微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 61.46% | 3.65% | 1.14% | 45/158 | 22.23% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 60.77% | -0.66% | 17.82% | 48/158 | 32.75% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 51.57% | -9.4% | -12.19% | 73/158 | 51.26% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 58.74% | 5.85% | -0.94% | 58/158 | 51.17% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 59.29% | 0.65% | -3.07% | 57/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 61.17% | -1.02% | 7.46% | 55/158 | 38.28% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 56.93% | -4.95% | 2.59% | 62/158 | 52.88% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 55.49% | -17.15% | -5.8% | 71/158 | 53.39% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 58.91% | -11.38% | -4.68% | 59/158 | 6.36% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 61.8% | -9.82% | 3.18% | 56/158 | 21.22% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 59.89% | -14.05% | -10.58% | 59/158 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 66.98% | -3.81% | 0.76% | 49/158 | 54.96% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 66.47% | -6.57% | -3% | 42/158 | 46.94% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 68.53% | -8.54% | -1.66% | 43/158 | 47.38% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 69.68% | -5.4% | 0.08% | 32/158 | 54.17% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 69.63% | -14.32% | -2.14% | 39/158 | -145.98% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 71.15% | -14.35% | -5.05% | 33/158 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 74.93% | -13.43% | 1.72% | 25/158 | 54.3% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 73.66% | -15.41% | -9.35% | 26/158 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 81.26% | -12.27% | -2.18% | 16/158 | -1213.5% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 83.06% | -10.4% | -4.02% | 9/158 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 86.55% | -6.38% | -0.62% | 9/158 | 55.32% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 87.09% | -5.62% | -5.98% | 5/158 | 51.34% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 92.63% | 3.05% | -0.08% | 4/158 | -207.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 92.7% | 5.72% | 0.28% | 3/158 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 92.44% | 7.74% | 0.18% | 3/158 | 53.57% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 92.28% | 9.03% | 2.66% | 3/158 | 54.06% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 89.89% | 6.31% | 2.51% | 6/158 | 52.5% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 87.69% | 4.32% | 2.2% | 3/158 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 85.8% | 3.36% | 1.38% | 5/158 | 47.95% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 84.63% | 1.75% | 0.1% | 5/158 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 84.55% | -0.11% | 0.59% | 8/158 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 84.06% | -0.69% | 1.26% | 5/158 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 83.01% | 126.04% | -0.2% | 5/158 | 46.61% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 83.18% | 138.01% | -1.73% | 4/158 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 84.65% | 118.44% | 0.01% | 6/158 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 84.64% | 125.86% | 130.47% | 4/158 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 36.73% | 9.93% | 5.08% | 52/158 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 34.95% | 80.72% | -9.81% | 46/158 | 43.46% | 舒泰神 | 94.4% | 行业排名> |
| 2014-12-31 | 38.75% | 3.26% | 3.41% | 56/158 | 43.42% | 舒泰神 | 94.16% | 行业排名> |
| 2014-09-30 | 37.47% | -6.89% | 12.17% | 38/158 | 42.01% | 舒泰神 | 94.49% | 行业排名> |
| 2014-06-30 | 33.41% | -22.83% | 72.76% | 44/158 | 41.2% | 贝达药业 | 96.53% | 行业排名> |
| 2014-03-31 | 19.34% | 81.78% | -48.47% | 57/158 | 40.59% | 舒泰神 | 94.32% | 行业排名> |